Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anthrax - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 24 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anthrax - Overview 8 Anthrax - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Anthrax - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Anthrax - Companies Involved in Therapeutics Development 26 Altimmune Inc 26 Aphios Corp 26 Aradigm Corp 27 Companhia Industrial Produtora de Antibioticos SA 27 ContraFect Corp 28 Crestone Inc 28 Dynavax Technologies Corp 29 Emergent BioSolutions Inc 29 GlaxoSmithKline Plc 30 Green Cross Corp 30 Grifols SA 31 Hawaii Biotech Inc 31 iBio Inc 32 Merck & Co Inc 32 Microbiotix Inc 33 NanoBio Corp 33 PaxVax Inc 34 Pfenex Inc 34 Protein Potential LLC 35 ProThera Biologics Inc 35 Soligenix Inc 36 Syntiron LLC 36 Tetraphase Pharmaceuticals Inc 37 VLP Biotech Inc 37 Anthrax - Drug Profiles 38 anthrax (virus like particles) vaccine - Drug Profile 38 anthrax + plague vaccine - Drug Profile 39 anthrax vaccine - Drug Profile 40 anthrax vaccine - Drug Profile 42 anthrax vaccine - Drug Profile 43 anthrax vaccine - Drug Profile 44 anthrax vaccine - Drug Profile 45 anthrax vaccine - Drug Profile 46 Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 47 ARD-3100 - Drug Profile 48 AV-7909 - Drug Profile 52 BDM-I - Drug Profile 55 CF-306 - Drug Profile 58 CF-307 - Drug Profile 59 CF-308 - Drug Profile 60 ciprofloxacin hydrochloride - Drug Profile 61 CPN-1311 - Drug Profile 62 DPX-Anthrax - Drug Profile 63 DV-230 - Drug Profile 66 epimerox - Drug Profile 67 EV-035 - Drug Profile 68 GC-1109 - Drug Profile 70 gepotidacin mesylate - Drug Profile 71 GREANX - Drug Profile 74 KKL-35 - Drug Profile 75 Marinus - Drug Profile 76 Monoclonal Antibody for Anthrax - Drug Profile 77 Monoclonal Antibody for Anthrax - Drug Profile 78 Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 79 Nasoshield - Drug Profile 80 PBI-220 - Drug Profile 82 Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 84 Protein to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 85 Px-563L - Drug Profile 87 Px-563L Second Generation - Drug Profile 89 raxibacumab - Drug Profile 90 Recombinant Proteins for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Anthrax - Drug Profile 91 RiVax + SGX-204 - Drug Profile 92 rPA-01 - Drug Profile 93 RPA-563 - Drug Profile 94 Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 95 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 96 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 97 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 99 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 100 solithromycin - Drug Profile 101 SparVax - Drug Profile 115 TP-271 - Drug Profile 120 Anthrax - Dormant Projects 123 Anthrax - Discontinued Products 126 Anthrax - Product Development Milestones 127 Featured News & Press Releases 127 Appendix 138 Methodology 138 Coverage 138 Secondary Research 138 Primary Research 138 Expert Panel Validation 138 Contact Us 138 Disclaimer 139
List of Tables
Number of Products under Development for Anthrax, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Anthrax - Pipeline by Altimmune Inc, H2 2017 Anthrax - Pipeline by Aphios Corp, H2 2017 Anthrax - Pipeline by Aradigm Corp, H2 2017 Anthrax - Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2017 Anthrax - Pipeline by ContraFect Corp, H2 2017 Anthrax - Pipeline by Crestone Inc, H2 2017 Anthrax - Pipeline by Dynavax Technologies Corp, H2 2017 Anthrax - Pipeline by Emergent BioSolutions Inc, H2 2017 Anthrax - Pipeline by GlaxoSmithKline Plc, H2 2017 Anthrax - Pipeline by Green Cross Corp, H2 2017 Anthrax - Pipeline by Grifols SA, H2 2017 Anthrax - Pipeline by Hawaii Biotech Inc, H2 2017 Anthrax - Pipeline by iBio Inc, H2 2017 Anthrax - Pipeline by Merck & Co Inc, H2 2017 Anthrax - Pipeline by Microbiotix Inc, H2 2017 Anthrax - Pipeline by NanoBio Corp, H2 2017 Anthrax - Pipeline by PaxVax Inc, H2 2017 Anthrax - Pipeline by Pfenex Inc, H2 2017 Anthrax - Pipeline by Protein Potential LLC, H2 2017 Anthrax - Pipeline by ProThera Biologics Inc, H2 2017 Anthrax - Pipeline by Soligenix Inc, H2 2017 Anthrax - Pipeline by Syntiron LLC, H2 2017 Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 Anthrax - Pipeline by VLP Biotech Inc, H2 2017 Anthrax - Dormant Projects, H2 2017 Anthrax - Dormant Projects, H2 2017 (Contd..1), H2 2017 Anthrax - Dormant Projects, H2 2017 (Contd..2), H2 2017 Anthrax - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
